Stugeron tablets contain the active ingredient cinnarizine, which is a type of medicine called an antihistamine. It is used to prevent and treat motion sickness, relieve nausea, vomiting, attacks of dizziness or spinning sensations (vertigo) and sensations of ringing or other noise in the ears (tinnitus) associated with Meniere's disease and other middle ear disorders.
As with other antihistamines, STUGERON tablets may cause epigastric distress; taking it after meals may diminish gastric irritation.
Adults and children over the age of 12 years:
Peripheral circulatory disorders: 2-3 x 25 mg tablets three times daily.
Disorders of balance: 1 x 25 mg tablet three times daily.
The maximum recommended dosage should not exceed 225 mg (9 tablets) daily - if necessary the dosage may be divided over 2 or 3 intakes per day. As the effect of STUGERON tablets on vertigo is dose dependent, the dosage should be increased progressively.
Adults: 25 mg may be taken 2 hours before the start of the journey and 12.5 mg to 25 mg may be repeated every 8 hours during the journey when necessary.
Children 8 to 12 years: 12.5 mg (half a tablet) three times daily when necessary.
Children 5 to 7 years: 6.25 mg three times daily when necessary.
The most common antihistaminic side-effect of cinnarizine is sedation which can vary from slight drowsiness to deep sleep, and including inability to concentrate, lassitude, dizziness, and inco-ordination. Sedative effects, when they occur, may diminish after a few days.
Other side-effects include gastro-intestinal disturbances such as nausea, vomiting, diarrhoea or constipation, anorexia or increased appetite and epigastric pain.
Somnolence and gastro-intestinal disturbances are usually transient and may often be prevented by achieving the optimum dosage gradually.
Cinnarizine may also produce antimuscarinic effects such as blurred vision, difficulty in micturition, dysuria, dryness of mouth and tightness of chest.
Central effects may include muscular weakness, headache and euphoria.
Weight gain, perspiration or allergic reactions may be observed. Cases of lichen planus and lupus-like symptoms and an isolated case of cholestatic jaundice have been reported.
In elderly people cases of aggravation or an appearance of extrapyramidal symptoms sometimes associated with depressive feelings have been described during prolonged therapy. The treatment should be discontinued in such cases.
Cinnarizine may enhance the sedative effect of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, tricyclic antidepressants, sedatives and tranquillisers.
The side-effects of anticholinergic substances such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of antihistamines.
Monoamine-oxidase inhibitors may enhance the antimuscarinic effects of antihistamines.
Because of its antihistamine effect, cinnarizine may prevent otherwise positive reactions to dermal reactivity indicators if used up to 4 days prior to skin testing.
SIDE EFFECTS that may occur while using this medicine include:
Disturbances of the gut such as diarrhea, constipation, nausea, vomiting or abdominal pain.
Weight gain (rarely with long-term use)
Abnormal movements of the hands, legs, face, neck and tongue, eg tremor, twitching, rigidity (rarely with long-term use, mostly in elderly people - stop taking this medicine and consult your doctor if this occurs).
Skin reactions (very rarely with long-term use).
Jaundice (very rarely with long-term use).
If you notice other effects not listed above, contact your doctor, nurse, or pharmacist.